Cited by 434Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Mahaffey, Kenneth W., Wojdyla, Daniel M., Carroll, Kevin, Becker, Richard C., Storey, Robert F., Angiolillo, Dominick J., Held, Claes, Cannon, Christopher P., James, Stefan, Pieper, Karen S., Horrow, Jay, Harrington, Robert A., Wallentin, Lars·2011·Circulation

DOI 10.1161/circulationaha.111.047498

Open this paper in CoChat — free account

Abstract

Background—: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, a prespecified subgroup analysis showed a significant interaction between treatment and region ( P =0.045), with less effect of ticagrelor in North America than in the rest of the world. Methods and Results—: Reasons for the interaction were explored independently by 2 statistical groups. Systematic errors in trial conduct were investigated. Statistical approaches evaluated the likelihood of play of chance. Cox regression analyses were performed to quantify how much of the regional interaction could be explained by patient characteristics and concomitant treatments, including aspirin maintenance therapy. Landmark Cox regressions at 8 time points evaluated the association of selected factors, including aspirin dose, with outcomes by treatment. Systematic errors in trial conduct were ruled out. Given the large number of subgroup analyses performed and that a result numerically favoring clopidogrel in at least 1 of the 4 prespecified regions could occur with 32% probability, chance alone cannot be ruled out. More patients in the United States (53.6%) than in the rest of the world (1.7%) took a median aspirin dose ≥300 mg/d. Of 37 baseline and postrandomization factors explored, only aspirin dose explained a substantial fraction of the regional interaction. In adjusted analyses, both Cox regression with median maintenance dose and landmark techniques showed that, in patients taking low-dose maintenance aspirin, ticagrelor was associated with better outcomes compared with clopidogrel, with statistical superiority in the rest of the world and similar outcomes in the US cohort. Conclusions—: The regional interaction could arise from chance alone. Results of 2 independently performed analyses identified an underlying statistical interaction with aspirin maintenance dose as a possible explanation for the regional difference. The lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of concomitant aspirin. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00391872.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.047498

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation
Authors Task Force Members, de Werf, F. V., Bax, J. J., Betriu, A., Blomström‐Lundqvist, C., Crea, F., Falk, V., Filippatos, G. S., Fox, K. A. A., Huber, K., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn416 · Cited by 2,309
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,972
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
Bassand, J., Hamm, C. W., Ardissino, D., Boersma, E. H., Budaj, A., Fernández‐Avilés, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., Wallentin, L. C., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,860
Self-citation
Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction
Lee, K. L., Woodlief, L. H., Topol, E. J., Weaver, W. D., Betriu, A., Col, J. J., Simoons, M. L., Aylward, P. E., de Werf, F. V., & Califf, R. M. (1995) · Circulation · doi:10.1161/01.cir.91.6.1659 · Cited by 1,093
Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment Elevation
Boersma, E. H., Pieper, K. S., Steyerberg, E. W., Wilcox, R. G., Chang, W.-C., Lee, K. L., Akkerhuis, K. M., Harrington, R. A., Deckers, J. W., Armstrong, P. W., et al. (2000) · Circulation · doi:10.1161/01.cir.101.22.2557 · Cited by 962
Self-citation
Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
The CURRENT–OASIS 7 Investigators (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909475 · Cited by 767
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
FitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., & BRASH, A. R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110814 · Cited by 662
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G. R., & Storey, R. F. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.053 · Cited by 496
Self-citation
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
James, S. K., Åkerblom, A., Cannon, C. P., Emanuelsson, H., Husted, S., Katus, H. A., Skene, A. M., Steg, P. G., Storey, R. F., Harrington, R. A., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.01.003 · Cited by 404
Self-citation

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 1

Wallentin L Becker RC Budaj A Cannon CP Emanuelsson H Held C Horrow J Husted S James S Katus H Mahaffey KW Scirica BM Skene A Steg PG Storey RF Harrington RA; PLATO Investigators Freij A Thorsén M . Ticagrelor versus clopidogrel in patients with acute coronary syndromes [supplement]. N Engl J Med. 2009;361:1045–1057 e1–e34. http://www.nejm.org/doi/suppl/10.1056/NEJMoa0904327/suppl_file/nejm_wallentin_1045sa1.pdf. Accessed June 10 2011. · DOI · Paper page

Sorted by citations

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C.-T., Fesmire, F. M., Franklin, B. A., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,802
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P. H., Mauri, L., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 3,041
Self-citation
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Levine, G. N., Bates, E., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.513 · Cited by 1,658
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis‐Holland, J. E., Bangalore, S., Bates, E., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,691
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000404 · Cited by 1,355
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Lawton, J. S., Tamis‐Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001038 · Cited by 1,349
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary
Amsterdam, E. A., WENGER, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H. M., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000133 · Cited by 1,266
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
Jneid, H. M., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Lincoff, A. M., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318256f1e0 · Cited by 1,091
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 968
Ticagrelor or prasugrel in patients with acute coronary syndromes
Schüpke, S., Neumann, F.-J., Menichelli, M., Mayer, K., Bernlochner, I., Wöhrle, J., Richardt, G., Liebetrau, C., Witzenbichler, B., Antoniucci, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908973 · Cited by 816
Self-citation
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
Vranckx, P., Valgimigli, M., Jüni, P., Hamm, C. W., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 823
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary
Amsterdam, E. A., WENGER, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H. M., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.016 · Cited by 782
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.009 · Cited by 668
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
Jneid, H. M., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Lincoff, A. M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.004 · Cited by 481
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P. H., Mauri, L., et al. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx334 · Cited by 421
Self-citation
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
Rothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31133-4 · Cited by 353
Novel antiplatelet agents in acute coronary syndrome
Franchi, F., & Angiolillo, D. J. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.156 · Cited by 358
Self-citation
World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI
Levine, G. N., Jeong, Y., Goto, S., Anderson, J. L., Huo, Y., Mega, J. L., Taubert, K. A., & Smith, S. C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.104 · Cited by 337
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.07.044 · Cited by 304
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
Aradi, D., Storey, R. F., Komócsi, A., Trenk, D., Gulba, D. C., Kiss, R. G., Husted, S., Bonello, L., Sibbing, D., Collet, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht375 · Cited by 278
Self-citation
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 275
Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
Dobesh, P. P., & Oestreich, J. H. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1477 · Cited by 242
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J. A., Rockhold, F. W., Plotnikov, A. N., Mundl, H., Strony, J. T., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30751-1 · Cited by 227
Self-citation
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0049-1 · Cited by 220
Self-citation
Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management
Park, D., Kwon, O., Jang, J., Yun, S., Park, H., Kang, D., Ahn, J., Lee, P. H., Lee, S., Park, S., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041766 · Cited by 210
2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction
Jneid, H. M., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S. Z., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.032 · Cited by 194
The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis
Badimón, L., Vilahur, G., Rocca, B., & Patrono, C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab003 · Cited by 182
2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
Jneid, H. M., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S. Z., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000032 · Cited by 172
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
You, S. C., Rho, Y., Bikdeli, B., Kim, J., Siapos, A., Weaver, J. C., Londhe, A. A., Cho, J., Park, J., Schuemie, M. J., et al. (2020) · JAMA · doi:10.1001/jama.2020.16167 · Cited by 167
Antithrombotic Therapy in Patients With Chronic Kidney Disease
Capodanno, D., & Angiolillo, D. J. (2012) · Circulation · doi:10.1161/circulationaha.111.084996 · Cited by 163
Self-citation
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
Teng, R. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0290-2 · Cited by 160
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes
Tomaniak, M., Chichareon, P., Onuma, Y., Deliargyris, E., Takahashi, K., Kogame, N., Modolo, R., Chang, C. C., Rademaker-Havinga, T. A. M., Storey, R. F., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3355 · Cited by 138
Self-citation
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136
Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size
Nanhwan, M. K., Ling, S., Kodakandla, M., Nylander, S., Ye, Y., & Birnbaum, Y. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304002 · Cited by 134
Oral Antiplatelet Therapy After Acute Coronary Syndrome
Kamran, H., Jneid, H. M., Kayani, W. T., Virani, S. S., Levine, G. N., Nambi, V., & Khalid, U. (2021) · JAMA · doi:10.1001/jama.2021.0716 · Cited by 134
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin
Patrono, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.012 · Cited by 137
Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality
Rosselló, X., Huo, Y., Pocock, S., de Werf, F. V., Chin, C. T., Danchin, N., Lee, S. W. L., Medina, J., Vega, A., & Bueno, H. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.039 · Cited by 133
Protective Effects of Ticagrelor on Myocardial Injury After Infarction
Vilahur, G., Gutiérrez, M., Casaní, L., Varela, L. M., Capdevila, A., Pons‐Lladó, G., Carreras, F., Carlsson, L. G., Hidalgo, A., & Badimón, L. (2016) · Circulation · doi:10.1161/circulationaha.116.024014 · Cited by 124
Management of antiplatelet therapy in patients undergoing neuroendovascular procedures
Kim, K. S., Fraser, J. F., Grupke, S. L., & Cook, A. M. (2017) · Journal of neurosurgery · doi:10.3171/2017.5.jns162307 · Cited by 123
The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes
Angiolillo, D. J. (2012) · Drugs · doi:10.2165/11640880-000000000-00000 · Cited by 123
Self-citation
Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?
Eapen, Z. J., Reed, S. D., Li, Y., Kociol, R. D., Armstrong, P. W., Starling, R. C., McMurray, J. J. V., Massie, B. M., Swedberg, K. B., Ezekowitz, J. A., et al. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000265 · Cited by 124
Unstable Angina and Non–ST Elevation Myocardial Infarction
Braunwald, E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201109-1745ci · Cited by 115
Effects of P2Y12 receptor antagonists beyond platelet inhibition – comparison of ticagrelor with thienopyridines
Nylander, S., & Schulz, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13429 · Cited by 110
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy
Tanguay, J., Bell, A., Ackman, M. L., Bauer, R. D. C., Cartier, R., Chan, W., Douketis, J. D., Roussin, A., Schnell, G., Verma, S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.001 · Cited by 105
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial
Vranckx, P., Valgimigli, M., Windecker, S., Steg, P. G., Hamm, C. W., Jüni, P., García‐García, H. M., van Es, G., & Serruys, P. W. J. C. (2016) · EuroIntervention · doi:10.4244/eijy15m11_07 · Cited by 107
Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting
Jeong, H. S., Hong, S. J., Cho, S.-A., Kim, J.-H., Cho, J. Y., Lee, S. H., Joo, H. J., Park, J. H., Yu, C. W., & Lim, D. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.05.064 · Cited by 105
Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
Kazi, D. S., Garber, A. M., Shah, R. U., Dudley, R. A., Mell, M. W., Rhee, C., Moshkevich, S., Boothroyd, D. B., Owens, D. K., & Hlatky, M. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1999 · Cited by 108
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey
Cao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 101
Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes
Bhatt, D. L., Hulot, J., Moliterno, D. J., & Harrington, R. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302737 · Cited by 96
Self-citation
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
Vaduganathan, M., Bhatt, D. L., Cryer, B., Liu, Y., Hsieh, W.-H., Doros, G. D., Cohen, M. C., Lanas, Á., Schnitzer, T. J., Shook, T., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.068 · Cited by 93
Self-citation
Heart Failure Around the World
Tromp, J., Ferreira, J. P., Janwanishstaporn, S., Shah, M., Greenberg, B., Zannad, F. M., & Lam, C. S. P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1585 · Cited by 96
Contemporary Incidence and Predictors of Stent Thrombosis and Other Major Adverse Cardiac Events in the Year After XIENCE V Implantation
Naidu, S. S., Krucoff, M. W., Rutledge, D. R., Mao, V. W., Zhao, W., Qing, Z., Wilburn, O., Sudhir, K., Simonton, C. A., & Hermiller, J. B. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.02.014 · Cited by 92
Medical Management After Coronary Stent Implantation
Brilakis, E. S., PATEL, V. G., & Banerjee, S. (2013) · JAMA · doi:10.1001/jama.2013.7086 · Cited by 93
Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial
Schunkert, H., Boening, A., von Scheidt, M., Lanig, C., Gusmini, F., de Waha, A., Kuna, C., Fach, A., Grothusen, C., Oberhoffer, M. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz185 · Cited by 96
A Critical Appraisal of Aspirin in Secondary Prevention
Gargiulo, G., Windecker, S., Vranckx, P., Gibson, C. M., Mehran, R., & Valgimigli, M. (2016) · Circulation · doi:10.1161/circulationaha.116.023952 · Cited by 93
G-Protein–Coupled Receptors Signaling Pathways in New Antiplatelet Drug Development
Gurbel, P. A., Kuliopulos, A., & Tantry, U. S. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303412 · Cited by 92
The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease
Jones, W. S., Roe, M. T., Antman, E. M., Pletcher, M. J., Harrington, R. A., Rothman, R. L., Oetgen, W. J., Rao, S. V., Krucoff, M. W., Curtis, L. H., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.781 · Cited by 86
Self-citation
Antiplatelet therapy: new pharmacological agents and changing paradigms
Capodanno, D., Ferreiro, J. L., & Angiolillo, D. J. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12219 · Cited by 85
Self-citation
Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response
Gross, A. S., Harry, A., Clifton, C. S., & Pasqua, O. E. D. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15242 · Cited by 79
Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications
Floyd, C. N., Passacquale, G., & Ferro, A. (2012) · Clinical Pharmacokinetics · doi:10.2165/11630740-000000000-00000 · Cited by 74
New Directions in Antiplatelet Therapy
Ferreiro, J. L., & Angiolillo, D. J. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.966176 · Cited by 72
Self-citation
Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)
Crescente, M., Menke, L., Chan, M. V., Armstrong, P. C. J., & Warner, T. D. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14196 · Cited by 78
Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors
Siller-Matula, J. M., Trenk, D., Krähenbühl, S., Michelson, A. D., & Delle‐Karth, G. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12445 · Cited by 67
Diagnosis and Management of Ischemic Heart Disease
Franchini, M., Cervellin, G., & Lippi, G. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1333543 · Cited by 65
International differences in treatment effect: do they really exist and why?†
Pocock, S., Calvo, G., Marrugat, J., Prasad, K., Tavazzi, L., Wallentin, L. C., Zannad, F. M., & Garcia, A. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht071 · Cited by 66
Self-citation
Safety and Effectiveness of Contemporary P2Y 12 Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population‐Based Cohort Study
Yun, J. E., Kim, Y. J., Park, J. J., Kim, S., Park, K., Cho, M. S., Nam, G., & Park, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012078 · Cited by 64
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes
Wiviott, S. D., & Steg, P. G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60213-6 · Cited by 64
“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
Larmore, C. J., Effron, M. B., Molife, C., DeKoven, M., Zhu, Y. E., Lu, J., Karkare, S. U., Lieu, H. D., Lee, W. C., & Vetrovec, G. W. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26279 · Cited by 64
Synergistic Inhibition of Both P2Y 1 and P2Y 12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis
Gremmel, T., Yanachkov, I. B., Yanachkova, M. I., Wright, G. E., Wider, J. M., Undyala, V. V. R., Michelson, A. D., Frelinger, A. L., & Przyklenk, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306885 · Cited by 64
The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease
Johnston, A., Jones, W. S., & Hernandez, A. F. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0749-2 · Cited by 62
Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial
Tobbia, P., Brodie, B. R., Witzenbichler, B., Metzger, C., Guagliumi, G., Yu, J., Kellett, M. A., Stuckey, T., Fahy, M. P., Mehran, R., et al. (2013) · EuroIntervention · doi:10.4244/eijv8i10a176 · Cited by 59
Newer agents in antiplatelet therapy: a review
Holinstat, M. A., & Yeung, J. (2012) · Journal of Blood Medicine · doi:10.2147/jbm.s25421 · Cited by 57
Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey
Caroff, J., Aubert, L., Lavenu‐Bombled, C., Figueiredo, S., Habchi, K., Cortese, J., Eugène, F., Ognard, J., Tahon, F., Forestier, G., et al. (2022) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2021-018601 · Cited by 55
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial
Vranckx, P., Valgimigli, M., Odutayo, A., Serruys, P. W. J. C., Hamm, C. W., Steg, P. G., Heg, D., Fadden, E. P. M., Onuma, Y., Benit, E., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.119.015560 · Cited by 53
Modern Management of ST-Segment Elevation Myocardial Infarction
Frampton, J., DeVries, J. T., Welch, T. D., & Gersh, B. J. (2018) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.08.005 · Cited by 53
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors
Koziński, M., Ostrowska, M., Fabiszak, T., Navarese, E. P., Paciorek, P., Grześk, G., Kubica, J., & Adamski, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0915 · Cited by 51
New Approaches to Inhibiting Platelets and Coagulation
Depta, J. P., & Bhatt, D. L. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124438 · Cited by 51
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction
Xian, Y., Wang, T. Y., McCoy, L. A., Effron, M. B., Henry, T. D., Bach, R. G., Zettler, M. E., Baker, B., Fonarow, G. C., & Peterson, E. D. (2015) · Circulation · doi:10.1161/circulationaha.114.014992 · Cited by 51
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors
Winter, M., Grove, E. L., Caterina, R. D., Gorog, D. A., Ahrens, I., Geisler, T., Gurbel, P. A., Tantry, U. S., Navarese, E. P., & Siller-Matula, J. M. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw044 · Cited by 50
Rescuing clinical trials in the United States and beyond: A call for action
Eapen, Z. J., Vavalle, J. P., Granger, C. B., Harrington, R. A., Peterson, E. D., & Califf, R. M. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.02.003 · Cited by 46
Self-citation
Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta‐analysis of Randomized Controlled Trials
Sardar, P., Udell, J. A., Chatterjee, S., Bansilal, S., Mukherjee, D., & Farkouh, M. E. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001577 · Cited by 45
Novel agents for anti-platelet therapy
Ji, X., & Hou, M. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-44 · Cited by 45
Antiplatelet agents for chronic kidney disease
Natale, P., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Razavian, M., Craig, J. C., Jardine, M., Webster, A. C., & Strippoli, G. F. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008834.pub4 · Cited by 45
World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI
Levine, G. N., Jeong, Y., Goto, S., Anderson, J. L., Huo, Y., Mega, J. L., Taubert, K. A., & Smith, S. C. (2014) · Global Heart · doi:10.1016/j.gheart.2014.08.001 · Cited by 43
Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents
Angiolillo, D. J., & Ferreiro, J. L. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0022-7 · Cited by 42
Self-citation
Historical Lessons in Translational Medicine
Fitzgerald, D. J., & FitzGerald, G. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300271 · Cited by 46
Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers
Teng, R., Maya, J. F., & Butler, K. A. (2012) · Platelets · doi:10.3109/09537104.2012.748185 · Cited by 42
Aspirin, Clopidogrel, and Ticagrelor in Acute Coronary Syndromes
Berger, J. S. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.04.055 · Cited by 39
Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin
Binsaleh, N. K., Wigley, C. A., Whitehead, K. A., van Rensburg, M., Reynisson, J., Pilkington, L. I., Barker, D. L. A., Jones, S., & Dempsey‐Hibbert, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.014 · Cited by 41
Is aspirin useful in primary prevention?
Cleland, J. G. F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht287 · Cited by 40
Platelet Function Testing in Contemporary Clinical and Interventional Practice
Franchi, F., Rollini, F., Cho, J. R., Ferrante, E., & Angiolillo, D. J. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0300-y · Cited by 40
Self-citation
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions
Moertl, D., Chen, L., Coyle, D., Wells, G. A., & Steiner, S. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0586 · Cited by 39
Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms
Buccheri, S., Capodanno, D., James, S. K., & Angiolillo, D. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1680637 · Cited by 40
Self-citation
Ticagrelor: clinical development and future potential
Sanderson, N. C., Parker, W. A., & Storey, R. F. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202044 · Cited by 40
Self-citation
Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
Yu, J., Mehran, R., Dangas, G., Claessen, B. E. P. M., Baber, U., Xu, K., Parise, H., Fahy, M. P., Lansky, A. J., Witzenbichler, B., et al. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.07.016 · Cited by 38
Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA Perspective
Khin, N. A., Yang, P., Hung, H., Maung-U, K., Chen, Y.-F., Meeker-O’Connell, A., Okwesili, P., Yasuda, S. U., Ball, L. K., Sm, H., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.70 · Cited by 38

Authors: Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., Held, C., Cannon, C. P., James, S., Pieper, K. S., Horrow, J., Harrington, R. A., & Wallentin, L.
Affiliations: Uppsala University (SE)
ORCID: Mahaffey, Kenneth W.
Wojdyla, Daniel M.
Carroll, Kevin
Becker, Richard C.
Storey, Robert F.
Angiolillo, Dominick J.
Held, Claes
Cannon, Christopher P.
James, Stefan
Pieper, Karen S.
Horrow, Jay
Harrington, Robert A.
Wallentin, Lars
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-08-02
Volume: 124
Issue: 5
Pages: 544-554
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.111.047498
OpenAlex: W2085260510
Cited by: 434
References: 20
Citations by year: 2026: 2 · 2025: 11 · 2024: 10 · 2023: 13 · 2022: 19 · 2021: 19 · 2020: 16 · 2019: 29 · 2018: 20 · 2017: 32 · 2016: 37 · 2015: 38 · 2014: 52 · 2013: 55 · 2012: 68
FWCI: 40.98
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Duke Clinical Research Institute
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: ticagrelor, clopidogrel, PLATO trial, regional interaction, platelet aggregation inhibition, antiplatelet therapy, cardiovascular mortality, myocardial infarction, stroke, subgroup analysis
MeSH terms: Clopidogrel, Ticagrelor, Adenosine, Aged, Aspirin, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk Factors, Ticlopidine, United States, Global Health, Proportional Hazards Models, Stroke, Purinergic P2Y Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks